Traditional Chinese medicine patterns and targeted therapy for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial studies how traditional Chinese medicine (TCM) patterns relate to the effectiveness of EGFR-targeted pills in people with non-small cell lung cancer and an EGFR mutation. It aims to help match treatments more personally and may help improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-small cell lung cancer (the most common type of lung cancer).
- You are 18 years or older.
- You are generally able to care for yourself (up to being in bed less than half the day).
- You have an EGFR mutation, which is a specific change in the cancer cells that can be targeted by certain pills.
- You are either: (a) planning to take or currently taking an EGFR-targeted pill for 2 weeks after lung cancer surgery, or (b) your cancer is stage IIIB or IV (advanced) and you will start this pill as your first treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy (limertinib) combined with standard chemotherapy (carboplatin and etoposide) for people whose EGFR-positive lung cancer has transformed into small cell lung cancer after failing an EGFR inhibitor. The goal is to see if this combination can slow the cancer and help you live longer.
This study looks at how well patients with early-stage lung cancer (that has been surgically removed) do when treated with a targeted drug called EGFR-TKI to prevent cancer from coming back. Researchers will track actual patient outcomes in China from 2023 to 2026.
This trial is testing a new targeted pill for people with EGFR-positive non-small cell lung cancer. It's designed for those whose cancer has grown after other treatments, and it works by blocking a specific protein that helps the cancer grow.
This trial tests whether a targeted therapy pill (EGFR-TKI) can control small spots in the other lung after surgery for early-stage lung cancer. It's for people whose cancer has a specific EGFR gene change and who still have suspicious spots in the opposite lung after one side is removed.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
Hear when a new Non Small Cell Lung Cancer NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.